MARKET

ASLN

ASLN

Aslan Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.490
-0.040
-2.61%
Opening 11:48 09/21 EDT
OPEN
1.510
PREV CLOSE
1.530
HIGH
1.540
LOW
1.470
VOLUME
22.04K
TURNOVER
--
52 WEEK HIGH
8.18
52 WEEK LOW
0.3500
MARKET CAP
56.61M
P/E (TTM)
-1.1695
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ASLAN Pharmaceuticals Completes Enrolment In Second Cohort And Opens New Sites In US And Australia In ASLAN004 Atopic Dermatitis Study
SINGAPORE, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of
Benzinga · 5h ago
ASLAN Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
SINGAPORE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its presentation at the H.C. Wainwright 22nd Annual Global
GlobeNewswire · 09/10 08:08
SmileDirectClub, NanoViricides leads healthcare gainers, Aptorum, ADiTx Therapeutics among major losers
Gainers: SmileDirectClub (SDC) +23%, NanoViricides (NNVC) +17%, Entasis Therapeutics Holdings (ETTX) +15%, Nano-X Imaging (NNOX) +14%, Oak Street Health (OSH) +12%.Losers: Aptorum Group (APM) -18%, ADiTx Therapeutics (ADTX) -16%, Amarin Corporation (AMRN) -13.4%, Acutus Medical AFIB -13.3%, ASLAN Pharmaceuticals (ASLN) -11%.
Seekingalpha · 09/02 15:08
SmileDirectClub rallies on CEO boosting stake, NanoViricides surged on announcement of provide COVID-19 drug update on September 3, Aptorum stumbles on 1H results, ADiTx Therapeutics traded under pressure on pricing follow-on public offering
Gainers: SmileDirectClub (SDC) +23%, NanoViricides (NNVC) +17%, Entasis Therapeutics Holdings (ETTX) +15%, Nano-X Imaging (NNOX) +14%, Oak Street Health (OSH) +12%.Losers: Aptorum Group (APM) -18%, ADiTx Therapeutics (ADTX) -16%, Amarin Corporation (AMRN) -13.4%, Acutus Medical AFIB -13.3%, ASLAN Pharmaceuticals (ASLN) -11%.
Seekingalpha · 09/02 15:08
ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study
Interim, unblinded data from all 3 dose cohorts in MAD study expected in 4Q 2020SINGAPORE, Aug. 24, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives
GlobeNewswire · 08/24 08:27
ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference 2020
SINGAPORE, Aug. 07, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its pre
GlobeNewswire · 08/07 07:00
Aslan Pharma to delist from Taipei Exchange
ASLAN Pharmaceuticals (NASDAQ:ASLN) expects its ordinary shares to cease trading on Taipei Exchange (TPEx) on August 25, and therefore the ordinary shareho
seekingalpha · 07/17 16:11
ASLAN Pharma Reports Received Receipt Of Notice Of Delisting From Taipei Exchange In Further Progress Towards Primary Listing On Nasdaq
Benzinga · 07/17 10:11
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASLN stock price target is 5.50 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 3.93M
% Owned: 10.35%
Shares Outstanding: 37.99M
TypeInstitutionsShares
Increased
2
134.93K
New
5
-59.44K
Decreased
2
5.97K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.15%
Pharmaceuticals & Medical Research
-2.83%
Key Executives
Chairman/Director
Andrew Howden
Chief Executive Officer/Director
Carl Firth
Vice President - Finance
Kiran Asarpota
Vice President
Alison Ward
Other
Kenneth Kobayashi
Director
Damien Lim
Director
Jun Wu
Independent Director
Robert Hoffman
Independent Director
Chin-Feng Sun
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average ASLN stock price target is 5.50 with a high estimate of 6.00 and a low estimate of 5.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ASLN
ASLAN Pharmaceuticals Limited (ASLAN) is a clinical-stage immunology and oncology-focused biopharmaceutical company. ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aslan Pharmaceuticals Ltd (ADR) stock information, including NASDAQ:ASLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASLN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASLN stock methods without spending real money on the virtual paper trading platform.